日本非小细胞肺癌患者脑转移:预后评估及奥希替尼与免疫检查点抑制剂的使用——回顾性研究
该回顾性研究分析294例2013—2020年在北海道癌症中心新诊断脑转移并初始接受放疗的日本非小细胞肺癌患者,评估Lung-molGPA、PD-L1表达及治疗史对预后的影响。结果显示Lung-molGPA可成功分层预后,奥希替尼延长EGFR阳性腺癌患者生存,ICI在高PD-L1表达患者中有效。
要点
- Lung-molGPA可对日本NSCLC脑转移患者进行预后分层。
- EGFR阳性腺癌患者中,使用奥希替尼者中位OS 34.2个月 vs 未使用者17.6个月(p=0.0164)。
- PD-L1高表达患者中,接受ICI者中位OS 8.6个月 vs 未接受者3.6个月。
核心结论
- Lung-molGPA可成功对日本NSCLC脑转移患者进行预后分层。
- 奥希替尼延长EGFR阳性NSCLC脑转移患者生存,ICI在高PD-L1表达患者中有效。
研究设计与样本
- 回顾性分析294例2013—2020年在北海道癌症中心新诊断脑转移并初始接受放疗的NSCLC患者。
- 评估Lung-molGPA各项、PD-L1表达(分为高、低、无表达)及治疗史对预后的影响,主要结局为自脑转移诊断日起的生存,采用log-rank检验。
主要发现
- 腺癌患者按GPA评分0—1.0、1.5—2.0、2.5—3.0、3.5—4.0分组,中位OS分别为5.5、14.8、28.3、39.0个月(p<0.0001)。
- 非腺癌患者按GPA评分0—1.0、1.5—2.0、2.5—3.0分组,中位OS分别为3.2、11.0、16.0个月(p=0.0011)。
- 腺癌基因突变患者中,使用奥希替尼者中位OS 34.2个月 vs 未使用者17.6个月(p=0.0164)。
- 初始接受TKI治疗脑转移者与初始接受放疗者OS无显著差异(p=0.5337)。
- PD-L1高、低、无表达组脑转移诊断后中位生存分别为5.6、22.5、9.3个月(p=0.2198);高表达患者中,接受ICI者中位OS 8.6个月 vs 未接受者3.6个月。
关键数值与推荐
- 腺癌GPA评分0—1.0、1.5—2.0、2.5—3.0、3.5—4.0组中位OS分别为5.5、14.8、28.3、39.0个月(p<0.0001)。
- 非腺癌GPA评分0—1.0、1.5—2.0、2.5—3.0组中位OS分别为3.2、11.0、16.0个月(p=0.0011)。
- 腺癌基因突变患者使用奥希替尼者中位OS 34.2个月 vs 未使用者17.6个月(p=0.0164)。
- PD-L1高、低、无表达组中位生存分别为5.6、22.5、9.3个月(p=0.2198)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. RESULTS: The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). CONCLUSIONS: We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.
引用
- Higaki H, Nishioka K, Otsuka M, et al. Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study. Radiat Oncol. 2023. PMID: 36750899. doi:10.1186/s13014-023-02218-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。